A step in the right direction Performance Chemicals returned to growth in Q3 and beat our sales esti...
Redeye believes that Sdiptech’s Q3 report was in line with our expectations.
Redeye leaves its initial take on Stille's report for the third quarter of 2022, containing both pos...
Redeye will lower its estimates slightly on the back of this Q3 2022 report, which missed expectatio...
XVIVO delivers a Q3 with 35% organic (CER) growth which is booth solid and ahead of our expectations...
Redeye states that the Q3 report was considerably weaker than expected on both top line and bottom l...
Redeye states that the Q3 report was mixed, with higher profitability than expected but lower-than-e...
Q3 trading update released this morning (the company reports semi-annually, no quarterly consensus a...
CapMan reported Q3 EBIT of 12.7m, 7% above Refinitiv consensus.
Redeye makes slight forecast adjustments following Hoylu’s Q3 2022 report.
Redeye updates estimates and valuation on Stillfront following the company’s Q3-results which came i...
While Q3 was still burdened by high costs, we note the market environment looks to be starting to im...
Atria's Q3 adjusted EBIT of EUR 16.2m was in line with our expectations, supported by strong sales g...
Redeye retains its positive view of Fortnox despite somewhat lowering its short-term forecasts and r...
Redeye believes Formpipe’s Q3 was on the softer side due to the lower-than-expected ACV, following p...
Fortsatt stark efterfrågan… Lagercrantz växte försäljningen 11% organiskt och är därmed på rekordhög...
Redeye leaves its view on Pila Pharma following its report for the third quarter of 2022.
Tillväxten avtar i Q3 Bubblerooms omsättning för Q3 växte 2% i jämförbara enheter till 91,5 mkr.
Q3 svagare y/y på grund av satsningar på Online Bokusgruppen rapporterade en EBITA på 14,9 mkr, lägr...
Redeye is positive as regards the results from a new study, further showing statistically significan...
